Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H14N2O2S |
| Molecular Weight | 226.295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](S)[C@@H](CC1=CN=C(N)C=C1)C(O)=O
InChI
InChIKey=GYIYAOUGKJSCCG-HTRCEHHLSA-N
InChI=1S/C10H14N2O2S/c1-6(15)8(10(13)14)4-7-2-3-9(11)12-5-7/h2-3,5-6,8,15H,4H2,1H3,(H2,11,12)(H,13,14)/t6-,8-/m1/s1
| Molecular Formula | C10H14N2O2S |
| Molecular Weight | 226.295 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of the enantioselectivity of glycogen-based dual chiral selector systems towards basic drugs in capillary electrophoresis. | 2010-11-05 |
|
| The biosynthesis of papaverine proceeds via (S)-reticuline. | 2010-08 |
|
| Determination of atracurium, cisatracurium and mivacurium with their impurities in pharmaceutical preparations by liquid chromatography with charged aerosol detection. | 2010-02-19 |
|
| Laudanosine has no effects on respiratory activity but induces non-respiratory excitement activity in isolated brainstem-spinal cord preparation of neonatal rats. | 2010 |
|
| Use of intrathecal and intravenous clonidine in a case of severe tetanus with acute renal failure. | 2009-04 |
|
| Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca(2+)-activated K(+) channel blockers. | 2008-06-01 |
|
| Applicability of ultra-performance liquid chromatography-tandem mass spectrometry for heroin profiling. | 2008-04-25 |
|
| [Absorption of papaverine, laudanosine and cepharanthine across human intestine by using human Caco-2 cells monolayers model]. | 2008-02 |
|
| Synthesis of carbon-11 labeled 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolinium derivatives as new potential PET SKCa channel imaging agents. | 2008-02 |
|
| Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. | 2008 |
|
| Bioactive constituents of the roots of Polyalthia cerasoides. | 2007-09 |
|
| Simultaneous determination of atracurium and its metabolite laudanosine in post-mortem fluids by liquid chromatography/multiple-stage mass spectrometry on an ion trap. | 2007 |
|
| Anesthesiologist suicide with atracurium. | 2006-03 |
|
| Chiral separation of norlaudanosoline, laudanosoline, laudanosine, chlorthalidone, and three benzoin derivatives using amino acid based molecular micelles. | 2006-02 |
|
| SK channels control the firing pattern of midbrain dopaminergic neurons in vivo. | 2005-12 |
|
| Evaluation of benzyltetrahydroisoquinolines as ligands for neuronal nicotinic acetylcholine receptors. | 2005-09 |
|
| Perinatal neuroprotection by muscle relaxants against hypoxic-ischemic lesions: is it a possible hypothesis? | 2005-08 |
|
| Synthesis and biological evaluation of N-methyl-laudanosine iodide analogues as potential SK channel blockers. | 2005-02-15 |
|
| Transformation of opium poppy (Papaver somniferum L.) with antisense berberine bridge enzyme gene (anti-bbe) via somatic embryogenesis results in an altered ratio of alkaloids in latex but not in roots. | 2004-12 |
|
| The efficient synthesis of morphinandienone alkaloids by using a combination of hypervalent iodine(III) reagent and heteropoly acid. | 2004-10-11 |
|
| Instability of pancuronium in postmortem blood and liver taken after a fatal intramuscular Pavulon injection. | 2004-07-16 |
|
| The insulin pump as murder weapon: a case report. | 2004-06 |
|
| The GC-MS detection and characterization of reticuline as a marker of opium use. | 2004-05-28 |
|
| The GC-MS detection and characterization of reticuline as a marker of opium use. | 2004-03-10 |
|
| Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids. | 2004-03 |
|
| Aporphine alkaloids from Guatteria spp. with leishmanicidal activity. | 2003-07 |
|
| The possible neuroprotective effect of laudanosine, an atracurium and cisatracurium metabolite. | 2003-07 |
|
| Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage. | 2002-11 |
|
| Methyl-laudanosine: a new pharmacological tool to investigate the function of small-conductance Ca(2+)-activated K(+) channels. | 2002-09 |
|
| Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome. | 2002-08 |
|
| Colominic acid: a novel chiral selector for capillary electrophoresis of basic drugs. | 2002-07-12 |
|
| Laudanosine, an atracurium and cisatracurium metabolite. | 2002-07 |
|
| Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium? | 2002-04 |
|
| Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. | 2001-08 |
|
| The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. | 2001-08 |
|
| Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain. | 2001-07 |
|
| Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. | 2001-04 |
|
| Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. | 2001-01 |
|
| Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. | 1998-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:44:12 GMT 2025
by
admin
on
Tue Apr 01 18:44:12 GMT 2025
|
| Record UNII |
84KQ4M4N8B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
87609775
Created by
admin on Tue Apr 01 18:44:12 GMT 2025 , Edited by admin on Tue Apr 01 18:44:12 GMT 2025
|
PRIMARY | |||
|
DB05712
Created by
admin on Tue Apr 01 18:44:12 GMT 2025 , Edited by admin on Tue Apr 01 18:44:12 GMT 2025
|
PRIMARY | |||
|
84KQ4M4N8B
Created by
admin on Tue Apr 01 18:44:12 GMT 2025 , Edited by admin on Tue Apr 01 18:44:12 GMT 2025
|
PRIMARY | |||
|
775274-06-1
Created by
admin on Tue Apr 01 18:44:12 GMT 2025 , Edited by admin on Tue Apr 01 18:44:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
2.3.9 AZD-9684 (carboxypeptidase U inhib-Astr, CPU inhibitor-AstraZeneca) AZD-9684 (carboxypeptidase U inhib-Astr, CPU inhibitor-
AstraZeneca; AstraZeneca), a carboxypeptidase U (CPU)
inhibitor, was under development for the treatment of thrombosis. AZD-9684 inhibits CPU, which removes C-terminal lysines from partially degraded thrombin and impairs plasminogen activation and subsequent fibrinolysis. Phase II development was underway however,development has been discontinued.
|
||
|
ACTIVE MOIETY |
Fifty-eight patients with confirmed PE were randomized to receive AZD9684 or placebo, on top of once-daily dalteparin for 57 days. In the patient group receiving AZD9684, fibrinolysis biomarkers in plasma were higher and sustained for a longer period of time, implying that inhibition of CPU by AZD9684 stimulates endogenous fibrinolysis. Moreover, lung deficiency scintigraphy scores improved over the treatment period. In addition, no difference in the occurrence of adverse effects was seen between both treatment groups.
|
